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Supplementary Figure S1: A complete normalised gene expression pattern of human TJs in 
cultured human SCEC. SC65, 68, 76 and 77 SCEC strains were used for this study. Data are mean 
± s.e.m. 
 
 
 
 
Supplementary Figure S2: Comparison of claudin-11 and ZO-1 gene expression between 
cultured human TM and SCEC. Fold change in gene expression was determined by the 2-∆∆Ct 
method. Data represent mean fold change of SC77 and TM93 cell strains at two-passage numbers 
± s.e.m (n = 2). 
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Supplementary Figure S3: Immunostaining of claudin-5 and claudin-11 in frozen sections of 
mouse anterior segments. claudin-5 and claudin-11 = Cy3 (red); DAPI = blue; * = Schlemm’s 
canal lumen. 
 
 
 
 
Supplementary Figure S4: Western blot for claudin-5 in Schlemm’s canal endothelial cells 
dissected from five different non-human primates. BCF = mouse brain capillary fraction as 
positive control.  
 
 
Supplementary Figure S5: Cell viability essay on cultured SCEC treated with (a) 40 nM siRNA 
or (b) 200 nM siRNA. No significant difference was found between the negative control and any 
of the siRNA treated samples (n=4; one-way ANOVA with a Tukey's post-test). NEG = negative 
control; Vehicle = transfection reagents alone; NT = non-targeting siRNA; POS = positive control; 
Combo = combination of ZO-1, claudin-11 and tricellulin. 
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Supplementary Figure S6: a) Western blot analysis illustrating knockdown of ZO-1 in mouse 
brain endothelial cells (bEND3) 24 and 48 hr post-transfection. Data show average ± s.e.m. (n=2). 
b) Western blot analysis illustrating knockdown of tricellulin in HEK293 cells transfected with 
mouse tricellulin cDNA 24 and 72 hr post-siRNA transfection (n=4). NT: non-targeting siRNA. 
 
Supplementary Figure S7: Quantitative RT-PCR analysis illustrating knockdown of  ZO-1 and 
tricellulin transcript levels at 12 hrs post siRNA delivery in the mouse retina. n = 3, *P≤0.05. Data 
is mean fold change with max and min from ΔΔCt standard deviations. 
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Supplementary Figure S8. (a-f) IHC based TUNEL staining. (a) Negative control. (b) DNAase1 
treated positive control. (c-d) Representative non-targeting images showing minor fluorescence in 
the corneal epithelium and ciliary body. (e-f) Representative targeting images showing similar 
staining patterns to that of non-targeting controls. (g-i) Cleaved caspase-3 staining. (g) Negative 
control. (h) Non-targeting staining shows little to no signal in outflow tissues, and minor signal in 
the ciliary. (i) Similar staining was observed in targeting sections as a whole. (j) Caspase-3 
positive control. Representative scale bars denote 100 µm. Arrows = high incidence of apoptosis; 
Asterisk = SC lumen; C = cornea; AC = anterior chamber; CB = ciliary body. 
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Supplementary Figure S9: Representative flow (Q) vs. pressure (P) plot for a pair of eyes. Each 
data point shows the average of 4 min of stable flow at each pressure step, and error bars represent 
95% confidence intervals. A power-law model (see Methods) is fit to the data and the 95% 
confidence bounds of the fit are represented by the shaded areas.  
 
 
Supplementary Figure S10. (a) Western blots comparing Claudin-11, ZO-1 and Tricellulin 
protein expression between cultured healthy and glaucomatous SCEC monolayers. Histograms 
depict relative densitometric changes in protein expression from four independent experiments. 
(b) TEER values were measured in cultured glaucomatous SCEC strain (SC57g) and healthy 
SCEC strain (SC68) after one week of confluency was reached. Data represented as mean ± s.e.m. 
(unpaired Student’s t test).  
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Time post-
transfection 
(hr) 
NT siRNA 
(Ω.cm ± s.e.m.) 
n=6 
CLDN11 siRNA 
(Ω.cm ± s.e.m.) n=6 
ZO-1 siRNA 
(Ω.cm ± s.e.m.) 
n=6 
CLDN11 + ZO-1 
siRNA (Ω.cm ± s.e.m.) 
n=6 
0 10.64 ± 0.33 11.48 ± 0.28 10.64 ± 0.33 10.36 ± 0.55 
24 14.56 ± 0.00 12.60 ± 0.28 10.64 ± 1.00 12.88 ±0.33 
48 15.96 ± 0.55 12.60 ± 0.28 11.76 ± 1.00 7.84 ± 0.00 
72 15.12 ± 0.66 12.88 ± 0.00 10.08 ± 1.00 4.20 ± 0.55 
 
Time post-transfection (hr) NT siRNA (Ω.cm ± s.e.m.) n=4 Tricellulin siRNA (Ω.cm ± s.e.m.) n=4 
0 13.22 ± 0.38 13.66 ± 0.33 
24 13.66  ± 0.57 11.87 ± 1.09 
48 15.12 ± 0.30 10.98 ± 0.28 
72 15.57 ±0.48 11.42 ± 0.57 
 
Time post-transfection 
(hr) 
NT siRNA (Ω.cm ± s.e.m.) 
n=6 
CLDN11+ZO-1+Tric siRNA (Ω.cm ± 
s.e.m.) n=6 
0 16.32 ± 1.42 15.26 ± 0.79 
24 15.75  ± 1.74 7.77 ± 1.44 
48 14.88 ± 1.49 5.88 ± 0.91 
72 16.00 ± 1.49 10.50 ± 1.54 
 
Supplementary Table S1: Raw values from TEER measurements following treatment of SCEC 
monolayers with claudin-11, ZO-1, tricellulin, claudin-11 + ZO-1 siRNA or a combination of the 
three siRNAs. Data are Ω x cm2 ± s.e.m. 
 
 
 NT siRNA T siRNA Mouse Cr (nl/min/mmHg) x/ ME95 Cr  (nl/min/mmHg) x/ ME95 
1 4.5 1.23 12.9 1.03 
2 3.5 1.08 7.6 1.12 
3 6.3 1.04 9.2 1.09 
4 6.7 1.12 11.9 1.12 
5 4.4 1.08 7.8 1.06 
6 4.4 1.18 5.6 1.08 
7 3.3 1.08 18.1 1.06 
 
Supplementary Table S2: Facility values (Cr) for each pair of eyes together with the margin of 
error at 95% confidence level (ME95) measured 48 hr post-injection.  
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 NT siRNA T siRNA Mouse Cr (nl/min/mmHg) x/ ME95 Cr  (nl/min/mmHg) x/ ME95 
1 10.2 1.18 10.8 1.11 
2 13.0 1.02 11.7 1.06 
3 12.6 1.08 14.8 1.04 
4 13.7 1.04 16.9 1.11 
 
Supplementary Table S3: Facility values (Cr) for each pair of eyes together with the margin of 
error at 95% confidence level (ME95) measured 8 weeks post-injection.  
 
